Good MorningEquity markets rebounded on Thursday, erasing some but not all of Wednesday's losses. The move in the S&P 500 was largely driven by tech, led by a 20% gain in Tesla. Tesla reported a mixed quarter with a wider-than-expected margin; the news sending shares higher was the outlook for robust production and delivery growth in 2025. CEO Elon Musk estimates the growth at something like 20% to 30%, driven by a yet-to-be-seen lower-priced model.
The risk for the market next week is enormous, including earnings and economic data. The earnings deluge will continue with over 100 reports from S&P 500 Companies, including key reads from big tech names like Microsoft and Amazon. On the economic front, reports on third-quarter GDP, the PCE price index, and labor markets will drive the action. The risk is that weaker-than-expected data will raise the fear of a recession. Hot data is good news any way you look at it. The Fed may back off on the pace of interest rate cuts because of hot data, but economic and earnings growth will offset it and continue to drive stocks higher. Featured: Trump goes "all-in" on Grand Canyon energy breakthrough (Ad) 
|
Industrials | |
Space stocks have had plenty of reasons to soar this fall. Non-public Elon Musk venture SpaceX completed a significant flight test of its Starship in October, while NASA's Europa Clipper departed for Jupiter's moon. Meanwhile, AST SpaceMobile Inc. (NASDAQ: ASTS) has skyrocketed by nearly 800% in t... Read the Full Story |
|
From Our Partners | | Matt Monaco started with a $2,000 trading account and no clear strategy. After two years of trial and error, he crossed $1 million in 2020.
Today his account sits at $3 million, generating roughly $100,000 a month using a repeatable system he calls The Income Blueprint.
He's revealing the exact five-step scan and three trading lanes behind it in a free live training. | | Reserve your seat and claim The Income Blueprint free |
|
Markets | |
Meta Platforms Inc (NASDAQ: META) has been having a good year. Its ongoing rally, which kicked off around this time in 2022, is continuing to go from strength to strength and analysts are calling for even more gains ahead in the coming weeks.
With an eye-watering market cap of $1.4 trillion, th... Read the Full Story |
|
Industrials | |
Transportation stocks typically indicate the economy's current state, while airline stocks gauge the consumer cycle's direction instead. Recently, shares of Spirit Airlines Inc. (NYSE: SAVE) have nearly doubled after the company struck a new deal to help keep its debt burden flexible ahead of bond... Read the Full Story |
|
From Our Partners | | Palantir, Micron and SanDisk show how fast a stock can become the trade everyone suddenly wants. That's often when investors make their costliest mistake: arriving after the easy part of the move is gone.
A new premium eBook flags 7 stocks that may be worth knowing about before the broader crowd catches on. You don't need to buy any of them - just knowing what's quietly gaining attention can be useful. | | See the 7 stocks on the watchlist while it's still free |
|
Consumer Discretionary | |
Tesla (NASDAQ: TSLA) is a good company, but that doesn’t mean its stock price will have a significant rally anytime soon. The market for Tesla is valued in many different ways for many reasons, including its status as a vehicle OEM, an EV pure-play, a tech innovator, its energy business, AI,... Read the Full Story |
|
Consumer Discretionary | |
Lucid Group, Inc. (NASDAQ: LCID) has made headlines with its recent stock sale, raising a staggering $1.75 billion. CEO Peter Rawlinson has confidently declared that this will fuel the company’s operations "well into 2026," allowing them to ramp up production of the Gravity SUV and launch ne... Read the Full Story |
|
|
Industrials | |
Shares of Lockheed Martin (NYSE: LMT) and RTX (NYSE: RTX) are up by 40% and 80% since early 2024 and can continue to set new highs this year and next. Their businesses are thriving because of increased global demand, and they sustain growth, robust cash flow, and ample capital returns, which are p... Read the Full Story |
|
Communication Services | |
The technology sector has been the darling of the entire stock market since the aftermath of the COVID-19 pandemic, and most stocks in the space easily delivered double-digit rallies for investors. However, not all stocks in the sector are made—or treated—equal, which is where investor... Read the Full Story |
|
Consumer Discretionary | |
The future of the energy sector lies in the most attractive and developed alternative energy sources. While this might not be an immediate payoff for those backing the trend, it does serve as a good place to start allocating capital with the next decade in mind. Today, shares of Next Era Energy In... Read the Full Story |
|
Consumer Discretionary | |
The stock market is about to undergo a major global shift. Over the next decade, the generational wealth accumulated over the past ten years may shift into a stagnant phase, resembling Japan’s "Lost Decade" for U.S. stocks. The reason behind this view is pretty clear, and investors will unde... Read the Full Story |
|
Consumer Staples | |
WD-40 Company’s (NASDAQ: WDFC) results gave the market reason to pause, but the pause is over, and higher price points lie ahead. The critical takeaway is that this company is growing, investing in new opportunities, and driving sufficient cash flow to sustain a robust balance sheet and he... Read the Full Story |
|
Friday's Early Bird Stock Of The Day Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. | | View Today's Stock Pick |
|
